Novel Potential Janus Kinase Inhibitors with Therapeutic Prospects in Rheumatoid Arthritis Addressed by In Silico Studies
Molecules · 12.06.2023 · 28 (12) · 4699
DOI: 10.3390/molecules28124699 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 12.06.2023. Verfasst von Andrei-Flavius Radu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Arthritis, Rheumatoid, Autoimmune Diseases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Oradea.
Abstract (Originalsprache)
Rheumatoid arthritis (RA) is a debilitating autoimmune disorder with an inflammatory condition targeting the joints that affects millions of patients worldwide. Several unmet needs still need to be addressed despite recent improvements in the management of RA. Although current RA therapies can diminish inflammation and alleviate symptoms, many patients remain unresponsive or experience flare-ups of their ailment. The present study aims to address these unmet needs through in silico research, with a focus on the identification of novel, potentially active molecules. Therefore, a molecular docking analysis has been conducted using AutoDockTools 1.5.7 on Janus kinase (JAK) inhibitors that are either approved for RA or in advanced phases of research. The binding affinities of these small molecules against JAK1, JAK2, and JAK3, which are target proteins implicated in the pathophysiology of RA, have been assessed. Subsequent to identifying the ligands with the highest affinity for these target proteins, a ligand-based virtual screening was performed utilizing SwissSimilarity, starting with the chemical structures of the previously identified small molecules. ZINC252492504 had the highest binding affinity (−9.0 kcal/mol) for JAK1, followed by ZINC72147089 (−8.6 kcal/mol) for JAK2, and ZINC72135158 (−8.6 kcal/mol) for JAK3. Using SwissADME, an in silico pharmacokinetic evaluation showed that oral administration of the three small molecules may be feasible. Based on the preliminary results of the present study, additional extensive research is required for the most promising candidates to be conducted so their efficacy and safety profiles can be thoroughly characterized, and they can become medium- and long-term pharmacotherapeutic solutions for the treatment of RA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania.
- Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania.
- Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania.
ORCID-Profile: Andrei-Flavius Radu, Simona Gabriela Bungau, Andrei Paul Negru
Förderung
- University of Oradea
Zitieren
APA
Radu, A. F., Bungau, S. G., Negru, A. P., Uivaraseanu, B., & Bogdan, M. A. (2023). Novel Potential Janus Kinase Inhibitors with Therapeutic Prospects in Rheumatoid Arthritis Addressed by In Silico Studies. Molecules, 28(12), 4699. https://doi.org/10.3390/molecules28124699
Vancouver
Radu AF, Bungau SG, Negru AP, Uivaraseanu B, Bogdan MA. Novel Potential Janus Kinase Inhibitors with Therapeutic Prospects in Rheumatoid Arthritis Addressed by In Silico Studies. Molecules. 2023;28(12):4699. doi:10.3390/molecules28124699
BibTeX
@article{Radu2023,
author = {Radu, Andrei-Flavius and Bungau, Simona Gabriela and Negru, Andrei Paul and Uivaraseanu, Bogdan and Bogdan, Mihaela Alexandra},
title = {Novel Potential Janus Kinase Inhibitors with Therapeutic Prospects in Rheumatoid Arthritis Addressed by In Silico Studies},
journal = {Molecules},
year = {2023},
volume = {28},
number = {12},
pages = {4699},
doi = {10.3390/molecules28124699}
}
EUVIMED